| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
867,229 |
| 52
Week Range: |
$187.64 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
19,405 |
57,754 |
513,978 |
| Total Sell Value |
$0 |
$4,136,219 |
$11,851,618 |
$91,955,621 |
| Total People Sold |
0 |
2 |
7 |
9 |
| Total Sell Transactions |
0 |
2 |
21 |
74 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dansey Roger D |
President, R&D & CMO |
• – – |
2023-01-24 |
4 |
AS |
$135.00 |
$1,350,000 |
D/D |
(10,000) |
97,539 |
|
43% |
|
| Dansey Roger D |
President, R&D & CMO |
• – – |
2023-01-24 |
4 |
OE |
$72.64 |
$726,400 |
D/D |
10,000 |
107,539 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2023-01-24 |
4 |
AS |
$135.03 |
$675,134 |
D/D |
(5,000) |
85,113 |
|
43% |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2023-01-24 |
4 |
OE |
$39.15 |
$195,750 |
D/D |
5,000 |
90,113 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2023-01-17 |
4 |
AS |
$130.71 |
$75,548 |
D/D |
(578) |
85,113 |
|
50% |
|
| Romp Charles R |
EVP, Commercial U.S. |
• – – |
2022-12-20 |
4 |
AS |
$127.63 |
$144,094 |
D/D |
(1,129) |
58,475 |
|
50% |
|
| Dansey Roger D |
President, Research and Develo |
• – – |
2022-12-14 |
4 |
AS |
$135.00 |
$1,350,000 |
D/D |
(10,000) |
97,539 |
|
53% |
|
| Dansey Roger D |
President, Research and Develo |
• – – |
2022-12-14 |
4 |
OE |
$72.64 |
$771,628 |
D/D |
10,000 |
106,942 |
|
- |
|
| Simonian Nancy A |
Director |
– • – |
2022-12-12 |
4 |
OE |
$36.70 |
$321,125 |
D/D |
8,750 |
62,753 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2022-11-17 |
4 |
S |
$131.05 |
$1,092,056 |
D/D |
(8,333) |
85,691 |
|
-54% |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2022-11-17 |
4 |
OE |
$34.20 |
$284,989 |
D/D |
8,333 |
94,024 |
|
- |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2022-11-14 |
4 |
OE |
$76.86 |
$99,995 |
D/D |
1,301 |
85,691 |
|
- |
|
| Gryska David W |
Director |
– • – |
2022-11-11 |
4 |
S |
$129.10 |
$968,220 |
D/D |
(7,500) |
40,253 |
|
-50% |
|
| Epstein David R |
Chief Executive Officer |
• • – |
2022-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
107,389 |
107,389 |
|
- |
|
| Swain Sandra M |
Director |
– • – |
2022-11-09 |
4 |
A |
$0.00 |
$0 |
D/D |
778 |
778 |
|
- |
|
| Dansey Roger D |
Interim CEO & CMO |
• – – |
2022-10-17 |
4 |
AS |
$135.00 |
$1,350,000 |
D/D |
(10,000) |
97,539 |
|
31% |
|
| Dansey Roger D |
Interim CEO & CMO |
• – – |
2022-10-17 |
4 |
OE |
$65.11 |
$745,421 |
D/D |
10,000 |
99,743 |
|
- |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-08-31 |
4 |
AS |
$154.41 |
$553,422 |
D/D |
(3,584) |
67,183 |
|
-14% |
|
| Liu Jean I |
Chief Legal Officer |
• – – |
2022-08-31 |
4 |
AS |
$154.41 |
$563,304 |
D/D |
(3,648) |
84,390 |
|
-14% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2022-08-31 |
4 |
AS |
$154.41 |
$646,379 |
D/D |
(4,186) |
137,185 |
|
-14% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2022-08-31 |
4 |
AS |
$154.41 |
$174,952 |
D/D |
(1,133) |
59,604 |
|
-14% |
|
| Dansey Roger D |
Interim CEO & CMO |
• – – |
2022-08-31 |
4 |
AS |
$154.41 |
$775,006 |
D/D |
(5,019) |
97,539 |
|
-14% |
|
| Himes Vaughn B |
Chief Technical Officer |
• – – |
2022-08-16 |
4 |
AS |
$170.22 |
$259,918 |
D/D |
(1,527) |
70,767 |
|
-27% |
|
| Romp Charles R |
EVP, Commercial |
• – – |
2022-08-16 |
4 |
AS |
$170.22 |
$300,430 |
D/D |
(1,765) |
60,737 |
|
-27% |
|
| Simpson Todd E |
Chief Financial Officer |
• – – |
2022-08-16 |
4 |
AS |
$170.22 |
$334,813 |
D/D |
(1,967) |
141,371 |
|
-27% |
|
1805 Records found
|
|
Page 6 of 73 |
|
|
